Cranial Nerve Palsy Present Across CARTITUDE Trials in Multiple Myeloma

News
Article
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

Patients enrolled across the CARTITUDE trials who experienced cranial nerve palsy after treatment with cilta-cel were generally male.

Those with cytokine release syndrome or immune effector-associated neurotoxicity syndrome were not found to be at a higher risk of having cranial nerve palsy.

Those with cytokine release syndrome or immune effector-associated neurotoxicity syndrome were not found to be at a higher risk of having cranial nerve palsy.

A subgroup of patients with multiple myeloma receiving ciltacabtagene autoleucel (cilta-cel; Carvykti) across 3 different CARTITUDE trials experienced cranial nerve palsy (CNP) at a median of 3 weeks post-infusion, according to findings from a poster presentation from the 2024 Oncology Nursing Society Conference.1

Cases of CNP were experienced mostly in male patients and were low-grade, with most cases resolving after a short time on corticosteroid treatment. Additionally, those with cytokine release syndrome or immune effector-associated neurotoxicity syndrome (ICANS) were not found to be at a higher risk of having CNP.

This presentation assessed results from the phase 1/2 CARTITUDE-1 (NCT03548207), phase 2 CARTITUDE-2 cohorts A, B, and C (NCT04133636), and phase 3 CARTITUDE-4 studies (NCT04181827).2-4 CARTITUDE-1 (n = 97) included patients with relapsed/refractory multiple myeloma with 3 or more prior lines of therapy. In cohort A of CARTITUDE-2 (n = 20), patients with progressive multiple myeloma after 1 to 3 lines of prior therapy and who were refractory to lenalidomide (Revlimid) were included, cohort B (n = 19) included those with progressive multiple myeloma after early relapse, and cohort C (n = 20) included those with relapsed/refractory multiple myeloma. CARTITUDE-4 (n = 176) included patients with lenalidomide-refractory multiple myeloma and 1 to 3 prior lines of therapy.

To grade CNP adverse effects, the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 was used. For patients with CNP, cerebral spinal fluid analyses and MRI were performed at the investigator’s discretion. Additionally, in order to assess CNP, flow cytometry was used for peripheral blood levels of cilta-cel and CAR-positive T cells with memory phenotypes. A multiplex sandwich immunoassay measured the serum cytokine levels.

Across the 3 studies, CNP was observed in 6.3% of patients. Most CNP events were grade 2 and presented as facial nerve palsy, and 3 patients had impairment of an additional cranial nerve.

Overall, 81% of patients with CNP were male. Prior to CNP, 1 patient experienced grade 2 ICANS, and no patients with CNP had movement and neurocognitive toxicity. Post–cilta-cel use and before CNP, 5 patients had bacterial infections, and 2 had cytomegalovirus.

In CARTITUDE-1, 3.1% of patients had CNP; for CARTITUDE-2 cohort A, it was 5.0%, cohort B was 5.3%, and cohort C was 0%; and in CARTITUDE-4, it was 9.1%. The median time to onset of CNP was 22 days (range, 1-101). Regarding the laterality of CNP, 71.4% had unilateral CNP, and 28.6% had bilateral CNP.

CNP at a maximum severity of grade 3 occurred in 33.3% of patients in CARTITUDE-1 and 12.5% in CARTITUDE-4. Cranial nerve VII involvement occurred in 100% of patients in each group except for cohort C, which was not evaluated. Cranial nerve involvement plus cranial nerve VII occurred in 33.3% of patients in CARTITUDE-1 and 12.5% in CARTITUDE-4. The amount of resolved CNP was 100% for CARTITUDE-1 and CARTITUDE-2 cohorts A and B as well as 87.5% for CARTITUDE-4.

For 17 patients who received an MRI and 14 with CSF analysis, there was no evidence of infections or malignant causes. Of note, 7 patients had facial nerve enhancement based on MRI. Corticosteroids were given to 19 patients for a median duration of 15 days. In 21 patients, 90.5% had a resolution of CNP with a median duration of 66 days.

For patients who received the total steroid dose of 250 mg or more vs 250 mg or less, there was no difference in CNP duration.

References

  1. Bennett L, Kruyswijk S, Sidana S, et al. Incidence and management of cranial nerve impairments in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Presented at the 49th Annual Oncology Nursing Society Conference; April 24-28, 2024; Washington, DC.
  2. Martin T, Usmani SZ, Beredeja JG, et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022;41(suppl 6). doi.10.1200/JCO.22.00842
  3. Hillengass J, Cohen AD, Agha M, et al. The phase 2 Cartitude-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1–3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (Cohort B). ASTCT. 2024;30(suppl 2):S36-S37. doi.10.1016/j.jtct.2023.12.054
  4. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Roman Fabbricatore
July 25th 2025
Article

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.

Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 24th 2025
Article

Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Ariana Pelosci
July 23rd 2025
Article

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.